Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameSinomab Bio-B
Stock Code03681
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities專門研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司,主要研製以單克隆抗體為基礎的生物藥,並開發新化學實體。
Listing Date2019-11-12
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)香港皇后大道東183號合和中心54樓
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitesinomab.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 7.60 / shares
Offer Price RangeTo be extracted
Lot Size300 shares
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2019-10-31 to 2019-11-05
Global Offering Shares182,129,400 shares
HK Public Offer Shares (Initial)18,213,000 shares (10.0%)
Public Offer Lots (Initial)60,710lots (Pool A30,355lots,Pool B30,355lots)
International Placing Shares (Initial)163,916,400 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,006,240,400 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share34.0%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,384,183,440

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 300 HK$ 2,280
2 lots 600 HK$ 4,560
3 lots 900 HK$ 6,840
4 lots 1,200 HK$ 9,120
5 lots 1,500 HK$ 11,400
6 lots 1,800 HK$ 13,680
7 lots 2,100 HK$ 15,960
8 lots 2,400 HK$ 18,240
9 lots 2,700 HK$ 20,520
10 lots 3,000 HK$ 22,800
15 lots 4,500 HK$ 34,200
20 lots 6,000 HK$ 45,600
25 lots 7,500 HK$ 57,000
30 lots 9,000 HK$ 68,400
35 lots 10,500 HK$ 79,800
40 lots 12,000 HK$ 91,200
45 lots 13,500 HK$ 102,600
50 lots 15,000 HK$ 114,000
100 lots 30,000 HK$ 228,000
150 lots 45,000 HK$ 342,000
200 lots 60,000 HK$ 456,000
250 lots 75,000 HK$ 570,000
300 lots 90,000 HK$ 684,000
350 lots 105,000 HK$ 798,000
400 lots 120,000 HK$ 912,000
450 lots 135,000 HK$ 1,026,000
500 lots 150,000 HK$ 1,140,000
1,000 lots 300,000 HK$ 2,280,000
1,500 lots 450,000 HK$ 3,420,000
2,000 lots 600,000 HK$ 4,560,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
2,500 lots 750,000 HK$ 5,700,000
3,000 lots 900,000 HK$ 6,840,000
3,500 lots 1,050,000 HK$ 7,980,000
4,000 lots 1,200,000 HK$ 9,120,000
4,500 lots 1,350,000 HK$ 10,260,000
5,000 lots 1,500,000 HK$ 11,400,000
10,000 lots 3,000,000 HK$ 22,800,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 1.8B
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +441%

Valuation & Financials

Market Cap (at Offer Price)HK$ 8,653,667,440
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status最近完整財年(2018年)虧損約人民幣83.6百萬元
Period-End Cash Balance人民幣41.5百萬元
Listing Expenses~HK$ 105,042,840
Listing Expenses / Funds Raised~7.59%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20172018
Other income and gains, net 3,4118,666
Administrative expenses -6,992-8,996
Net finance costs -2,961-3,030
Profit before tax -51,901-83,610
Income tax expense 00
Profit for the year -51,901-83,610
Profit attributable to owners -47,974-83,610
Balance Sheet
Item 201720182019-04
Cash and cash equivalents 66,09641,512
Total current assets 126,82650,270
Total assets 161,63688,819
Total current liabilities 184,90728,419
Total liabilities 212,58861,413
Total equity -50,95227,406
Equity attributable to owners -50,95227,406
Interest-bearing borrowings 170,00010,00010,000
Cash Flow Statement
Item 201720182019-04
Net cash from operating activities -40,200-46,829
Net cash from investing activities 10,31521,466
Net cash from financing activities 89,035-3,555
Net increase in cash 59,150-28,918
Depreciation of PP&E 12,6171,075493
Depreciation of right-of-use assets 1,1034,2671,970
Purchase of PP&E -823-2,746-10,231
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 6.0
First Day OpenHK$ 7.3
First Day Change-21.05%
First Day Volume61345400.0
First Day Turnover421492000.0
Use of Proceeds
1、約50.00%或643.22百萬港元將分配至研發及商業化在研藥物; 2、約40.00%或514.58百萬港元將用于建設我們的蘇州生產基地,其主要用作我們核心產品SM03的商業化規模生產; 3、約10.00%或128.64百萬港元將用于我們的營運資金、擴大內部能力及其他一般企業用途。

Underwriting Syndicate

Joint Sponsors (2)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 ORIENT CAPITAL (HONG KONG) LIMITED CE BDN128
Overall Coordinators (2)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 ORIENT SECURITIES (HONG KONG) LIMITED CE AVD362
Joint Bookrunners (8)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 ORIENT SECURITIES (HONG KONG) LIMITED CE AVD362 CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536 国泰君安证券(香港)有限公司 CE ABY236 招银国际融资有限公司 CE AVM940 海通国际证券有限公司 CE AAF806 Fosun International Securities Limited CE AAF432 VICTORY SECURITIES COMPANY LIMITED CE ABN091
Joint Lead Managers (8)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 ORIENT SECURITIES (HONG KONG) LIMITED CE AVD362 CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536 国泰君安证券(香港)有限公司 CE ABY236 招银国际融资有限公司 CE AVM940 海通国际证券有限公司 CE AAF806 Fosun International Securities Limited CE AAF432 VICTORY SECURITIES COMPANY LIMITED CE ABN091

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 瑞捷软件科技(香港)有限公司 78,429,720 HKD — 5.67% — 6 months 2020-05-12
2 云南白药集团股份有限公司 392,155,440 HKD — 28.33% — 6 months 2020-05-12

Directors & Management

PositionChinese nameEnglish Name
Chairman梁瑞安—
Company Secretary鄭美珍—
No director data available.

Major Shareholders

Major Shareholders & Holdings緊隨紅股發行及全球發售完成後(假設超額配股權未獲行使),控股股東一致行動集團合共持有約38.71%;海南海藥持有約15.11%;Apricot Oversea持有約10.76%。
About this page

This page shows Sinomab Bio-B (03681) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect